Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-((2,4-diamino-5-pyrimidinyl)oxy)-4-isopropyl-2-methoxybenzenesulfonamide
2. Af-219
3. Benzenesulfonamide, 5-((2,4-diamino-5-pyrimidinyl)oxy)-2-methoxy-4-(1-methylethyl)-
4. Mk-7264
1. 1015787-98-0
2. Af-219
3. Mk-7264
4. Gefapixant [usan]
5. Ro4926219
6. Rg-1646
7. Ro-4926219
8. Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
9. 6k6l7e3f1l
10. R-1646
11. Af219
12. Rg1646
13. Mk-7264;af-219
14. R1646
15. 5-[(2,4-diaminopyrimidin-5-yl)oxy]-2-methoxy-4-(propan-2-yl)benzene-1-sulfonamide
16. C14h19n5o4s
17. 5-((2,4-diaminopyrimidin-5-yl)oxy)-4-isopropyl-2-methoxybenzenesulfonamide
18. 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
19. 5-[(2,4-diamino-5-pyrimidinyl)oxy]-4-isopropyl-2-methoxybenzenesulfonamide
20. 5-((2,4-diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamide
21. 5-[2,4-bis(azanyl)pyrimidin-5-yl]oxy-2-methoxy-4-propan-2-yl-benzenesulfonamide
22. Benzenesulfonamide, 5-((2,4-diamino-5-pyrimidinyl)oxy)-2-methoxy-4-(1-methylethyl)-
23. 5-((2,4-diamino-5-pyrimidinyl)oxy)-4-isopropyl-2-methoxybenzenesulfonamide
24. Gefapixant [inn]
25. Gefapixant (usan/inn)
26. Gefapixant [who-dd]
27. Unii-6k6l7e3f1l
28. Gtpl9540
29. Schembl1493905
30. Chembl3716057
31. Dtxsid401337212
32. Amy27911
33. Bcp26079
34. Ex-a2788
35. Gefapixant(af-219,mk-7264)
36. Bdbm50533006
37. Mfcd24539325
38. S6664
39. Akos037515637
40. Zinc116342482
41. Db15097
42. Af-219; Mk-7264
43. Ac-35643
44. As-78086
45. Bm170818
46. Sy282739
47. Hy-101588
48. Cs-0021727
49. Ro 4926219
50. J3.556.891c
51. D11349
52. A934898
53. 2-methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide
54. 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide
55. Af9
Molecular Weight | 353.40 g/mol |
---|---|
Molecular Formula | C14H19N5O4S |
XLogP3 | 0.7 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 5 |
Exact Mass | 353.11577528 g/mol |
Monoisotopic Mass | 353.11577528 g/mol |
Topological Polar Surface Area | 165 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 512 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
R - Respiratory system
R05 - Cough and cold preparations
R05D - Cough suppressants, excl. combinations with expectorants
R05DB - Other cough suppressants
R05DB29 - Gefapixant
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
About the Company : Glixx Laboratories Inc (Glixx) is a global leading company specializing in biological research chemicals, providing services to meet the needs of biomedical research markets. With ...
About the Company : Established in 1997, the PRECISE Group is a respected pharmaceutical company in India with an annual turnover of USD 40 million. Backed by a skilled regulatory team, a dedicated fo...
Details:
Lyfnua (gefapixant) is an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough or unexplained chronic cough in adults.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Lyfnua
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2023
Lead Product(s) : Gefapixant Citrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Declines to Approve Merck's Chronic Cough Drug
Details : Lyfnua (gefapixant) is an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough or unexplained chronic cough in adults.
Product Name : Lyfnua
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2023
Details:
MK-7264 (gefapixant), an investigational, orally administered, selective P2X3 receptor antagonist, is being developed for the potential treatment of refractory or unexplained chronic cough and was approved in Japan and Switzerland under the brand name Lyfnua®.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Lyfnua
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 21, 2023
Lead Product(s) : Gefapixant Citrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Receives Positive European Union CHMP Opinion for Gefapixant
Details : MK-7264 (gefapixant), an investigational, orally administered, selective P2X3 receptor antagonist, is being developed for the potential treatment of refractory or unexplained chronic cough and was approved in Japan and Switzerland under the brand name Ly...
Product Name : Lyfnua
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2023
Details:
Last week, the Japan Ministry of Health, Labor and Welfare (MHLW) approved LYFNUA® (gefapixant) Tablets 45 mg for adults with refractory or unexplained chronic cough.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Lyfnua
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2022
Lead Product(s) : Gefapixant Citrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Provides U.S. and Japan Regulatory Update for Gefapixant
Details : Last week, the Japan Ministry of Health, Labor and Welfare (MHLW) approved LYFNUA® (gefapixant) Tablets 45 mg for adults with refractory or unexplained chronic cough.
Product Name : Lyfnua
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2022
Details:
COUGH-1 and COUGH-2 are international Phase 3, randomized, double-blind, placebo-controlled, studies to evaluate the efficacy and safety of gefapixant in reducing cough frequency in adult participants with refractory or unexplained chronic cough.
Lead Product(s): Gefapixant Citrate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Lyfnua
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2020
Lead Product(s) : Gefapixant Citrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck’s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24...
Details : COUGH-1 and COUGH-2 are international Phase 3, randomized, double-blind, placebo-controlled, studies to evaluate the efficacy and safety of gefapixant in reducing cough frequency in adult participants with refractory or unexplained chronic cough.
Product Name : Lyfnua
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2020
Regulatory Info :
Registration Country : Norway
Brand Name : Lyfnua
Dosage Form : Tablet, film-coated
Dosage Strength : 45 mg
Packaging : Blisterpakning 56item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Global Sales Information
Market Place
ABOUT THIS PAGE
89
PharmaCompass offers a list of Gefapixant Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Gefapixant Citrate manufacturer or Gefapixant Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gefapixant Citrate manufacturer or Gefapixant Citrate supplier.
PharmaCompass also assists you with knowing the Gefapixant Citrate API Price utilized in the formulation of products. Gefapixant Citrate API Price is not always fixed or binding as the Gefapixant Citrate Price is obtained through a variety of data sources. The Gefapixant Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Gefapixant Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gefapixant Citrate, including repackagers and relabelers. The FDA regulates Gefapixant Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gefapixant Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Gefapixant Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Gefapixant Citrate supplier is an individual or a company that provides Gefapixant Citrate active pharmaceutical ingredient (API) or Gefapixant Citrate finished formulations upon request. The Gefapixant Citrate suppliers may include Gefapixant Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Gefapixant Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Gefapixant Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gefapixant Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gefapixant Citrate GMP manufacturer or Gefapixant Citrate GMP API supplier for your needs.
A Gefapixant Citrate CoA (Certificate of Analysis) is a formal document that attests to Gefapixant Citrate's compliance with Gefapixant Citrate specifications and serves as a tool for batch-level quality control.
Gefapixant Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Gefapixant Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gefapixant Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Gefapixant Citrate EP), Gefapixant Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gefapixant Citrate USP).